SCHEMBL9977688

SCHEMBL9977688

COCCc1cccc(C)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.42
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
KMT2A Q03164 1/20 0.42
CCR1 P32246 1/20 0.41
CCR8 P51685 1/20 0.41
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NOS2 P35228 2/20 0.39
NOS3 P29474 1/20 0.39
KCNH2 Q12809 3/20 0.38
P2RX7 Q99572 1/20 0.38
NOS1 P29475 1/20 0.37
HSD17B3 P37058 1/20 0.37
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8234820 0.87 KCNH2 (0.47) SMN1; SMN2MEN1OPRM1OPRD1KMT2A
SCHEMBL24916774 0.83 CCR1 (0.52) SMN1; SMN2MEN1OPRM1OPRD1KMT2A
SCHEMBL30201993 0.83 CCR1 (0.52) SMN1; SMN2MEN1OPRM1OPRD1KMT2A
SCHEMBL7752804 0.82 NOS2 (0.42) SMN1; SMN2MEN1OPRM1OPRD1KMT2A
SCHEMBL10144469 0.81 KCNH2 (0.54) SMN1; SMN2MEN1OPRM1OPRD1KMT2A
SCHEMBL791993 0.79 CCR1 (0.44) SMN1; SMN2MEN1OPRM1OPRD1KMT2A
SCHEMBL4049049 0.78 KCNH2 (0.41) CCR1NOS2KCNH2NOS1TSHR
SCHEMBL12710391 0.78 KCNH2 (0.37) NOS2KCNH2NOS1TSHR
SCHEMBL4047122 0.78 KCNH2 (0.46) CCR1NOS2KCNH2NOS1TSHR
SCHEMBL3511340 0.78 HTR7 (0.41) NOS2KCNH2NOS1KDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020150675-A1 COMPOUNDS AND USES THEREOF NUVATION BIO INC. (US) 2020-07-23 WO disclosed
EP-2900223-B1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2017-10-25 EP disclosed
US-20140057870-A1 BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS VANDERBILT UNIVERSITY (US) 2014-02-27 US disclosed
US-20120225844-A1 BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS JANSSEN-CILAG S.A. (ES) 2012-09-06 US disclosed
US-20120225844-A1 BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS JANSSEN-CILAG S.A. (ES) 2012-09-06 US disclosed
WO-2012083224-A1 BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS VANDERBILT UNIVERSITY (US) 2012-06-21 WO disclosed
US-7291644-B2 Indole derivatives ONO PHARMACEUTICALS CO., LTD. (JP) 2007-11-06 US disclosed
US-7291644-B2 Indole derivatives ONO PHARMACEUTICALS CO., LTD. (JP) 2007-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057870-A1 BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS GRM5, GRIK5, GRIN3A SMN1; SMN2 2857/4885MEN1 4377/4885OPRM1 232/4885
US-20120225844-A1 BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS GRM5, GRIK5, GRIN3A SMN1; SMN2 2857/4885MEN1 4377/4885OPRM1 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.